[1] Seto WK, Yuen MF. Nonalcoholic fatty liver disease in Asia: emerging perspectives. J Gastroenterol, 2017, 52:164-174.
[2] Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2018, 15: 11-20.
[3] Xu G, Ye J, Liu XJ, et al. Activation of pluripotent genes in hepatic progenitor cells in the transition of nonalcoholic steatohepatitis to pre-malignant lesions. Lab Invest, 2017, 97: 1201-17.
[4] Malhotra N, Beaton MD. Management of non-alcoholic fatty liver disease in 2015. World J Hepatology, 2015, 7: 2962-2967.
[5] Woods CP, Hazlehurst JM, Tomlinson JW. Glucocorticoids and non-alcoholic fatty liver disease. Steroid Biochem Mol. Biol, 2015, 154:94-103.
[6] Haque, Tanvir, R, et al. Intestinal microbiota in liver disease. Best Pract Res Clin Gastroenterol, 2016:133-142.
[7] Machado MV, Cortez-pinto H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci, 2016, 17: 1-20
[8] Shen F, Zheng RD, Sun XQ, et al. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease Shen F, Zheng R D, Sun X Q, et al. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatob Pancreatic Dis Int, 2017, 16:375-381.
[9] Doulberis M, Kotronis G, Glalamprinou D, et al. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Metab Clin Exp, 2017, 71:182-197.
[10] Abdul Hai A, Abdallah A, Malnick SDH. Influence of gut bacteria on development and progression of non-alcoholic fatty liver diseaseJ. World J Hepatology, 2015, 7: 1679-1684.
[11] Abdou R M, Zhu L, Baker R D, et al. Gut Microbiota of Nonalcoholic Fatty Liver Disease. Dig Dis Sci,2016, 61: 1268-1281.
[12] Usami M, MiyoshiI M, Yamashita H. Gut microbiota and host metabolism in liver cirrhosis. World J Gastroenterol, 2015, 21: 11597-11608.
[13] He X, Ji G, Jia W, et al. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics. Int J Mol Sci, 2016, 17: 300
[14] 陈裕荷, 詹柱, 胡鹏,等. 非酒精性脂肪性肝炎的治疗新尝试——脂蛋白脂酶激动剂. 中华肝脏病杂志, 2019, 027: 533-540.
[15] 赵文霞, 闫乐, 邵明义,等. 化痰祛湿活血方对非酒精性脂肪性肝炎大鼠 ADPN/AMPK/ACC通路的影响. 临床肝胆病杂志, 2017, 33: 932-936.
[16] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会, 范建高,等. 非酒精性脂肪性肝病防治指南(2018年更新版). 实用肝脏病杂志, 2018, v.21: 30-39.
[17] Byrne CD, Targher GJD. Easl–Easd–Easo Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate. Diabetologia, 2016, 59: 1141-1144.
[18] Sberna AL, Bouillet B, Rouland A, et al. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver diseas. Diabet Med, 2017, 35:1-7.
[19] Vilar Gomez E, Yasells Garcia A, Martinez Perez Y, et al. Development and Validation of a Noninvasive Prediction Model for Nonalcoholic Steatohepatitis Resolution After Lifestyle Intervention. Hepatology, 2016, 63: 1875-1887.
[20] Guarino M, Kumar P, Felser A, et al. Exercise Attenuates the Transition from Fatty Liver to Steatohepatitis and Reduces Tumor Formation in Mice. Cancers, 2020, 12:1407.
[21] Zhang Y, He H, Zeng Y P, et al. Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study. Lipids Health Dis, 2020, 19:134.
[22] Ross T T, Crowley C, Kelly K L, et al. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems. Cell Mol Gastroenter, 2020.Online ahead of print.
[23] Lawitz EJ, Coste A, Poordad F, et al. Acetyl-CoA carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol, 2018, 16: 1983-1991.e3.
[24] Boeckmans J, Natale A, Rombaut M, et al. Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists. Cell Biol Toxicol, 2020. Online ahead of print.
[25] Kumar DP, Caffrey R, Marioneaux J, et al. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease. Sci Rep,2020,10:9330.
[26] Sebastian, Larion, Sandeep, et.al. Clinical studies investigating the effect of vitamin E therapy in patients with NASH[J]. Clin Liver Dis, 2018, 11: 16-21.
[27] HERNANDEZ G V, SMITH V A, MELNYK M, et al. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH. AM J Physiol Gastrol, 2020, 318: G582-G609.
[28] Tanaka N, Aoyama T, Kimura S, et al. Targeting nuclear receptors for the treatment of fatty liver disease.Pharmacol Ther,2017,179:142-157.
[29] Shah RA, Kowdley KV. Obeticholic acid for the treatment of nonalcoholic steatohepatitis. Expert Rev Gastroent, 2020, 14: 311-21.
[30] 徐亮, 宓余强, 李萍. 非酒精性脂肪肝中医证型客观化研究. 中华中医药杂志, 2015, 030: 2544-2547.
[31] 刘杨, 李明磊, 贾飞, 等. 逍遥散对非酒精性脂肪性肝炎肝郁脾虚证大鼠TLR-4/TRIF信号转导通路的影响. 中国实验方剂学杂志, 2018, 24: 108-13.
[32] 陈成, 慕永平, 冯琴. 非酒精性脂肪性肝炎的中医病机特点探讨. 世界科学技术-中医药现代化, 2016, 18:1483-1487.
[33] 郑超君, 马卫成. 靶向肠道菌群在非酒精性脂肪性肝炎中的机制及治疗进展. 沈阳药科大学学报, 2019,36:944-948.
[34] Lefere S, Devisscher L, Tacke F. Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges.Expert Opin Investig Drugs,2020,29:89-92.
[35] Kirpich IA, Marsano LS, Mcclain CJ. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. Clin Biochem, 2015, 48: 923-30. |
